It’s been a long three days for Teva and AstraZeneca, both of which have faced myriad questions and significant stock moves since a midweek report that AZ chief exec Pascal Soriot had signed on as the new CEO of Teva.
read moreAfter taking a beating in countless press reports over its Zika vaccine partnership with the U.S. Army, Sanofi is hoping to clear the air with a flurry of letters to critical U.S. senators. More: Amid dustup over taxpayer-funded research, Sanofi
read moreThe road to blockbuster land is steeper and rougher than it used to be, and payer footprints are all over it. Consider the much-anticipated Dupixent. Even with early coverage secured with upfront negotiations, obstacles are hampering its path to patients’
read moreAlready under a number of investigations from state and federal authorities for its Subsys marketing, beleaguered Insys Therapeutics now faces yet another legal challenge, this time from insurance giant Anthem. More: Insurance giant takes Insys to court for 'creative, fraudulent,
read moreAs the federal fraud trial of “pharma bro” Martin Shkreli closes out its third week in New York, former allies of the embattled biotech entrepreneur are painting a picture of a charming ally who turned nasty upon learning he would
read moreHealth minister Lord O’Shaughnessy has unveiled a new package of support worth up to £86 million to help innovative UK businesses develop medical breakthroughs that are then used across the NHS. More: Gov’t unveils £86m package to support SMEs Source:
read more© 1994 - 2026 B.M. Pharmaceuticals